This is a preview of subscription content, log in via an institution to check access.
Reference
Guan X, et al. Differences in reimbursement listing of anticancer therapies in China: an observational study. BMJ Open : 6 Jan 2020. Available from: URL: http://dx.doi.org/10.1136/bmjopen-2019-031203
Rights and permissions
About this article
Cite this article
China adopts costly WHO listed anticancer drugs for reimbursement. PharmacoEcon Outcomes News 845, 6 (2020). https://doi.org/10.1007/s40274-020-6509-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6509-y